{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.6","upperLimit":"19.3","value":"12.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Months from first treatment until death or the last date of contact","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.","id":"OG000","title":"Treatment (Single-agent Depsipeptide)"}],"paramType":"MEDIAN","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"Max of 98 months","title":"Survival","type":"SECONDARY","unitOfMeasure":"months"}